Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
    • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Inside the Corner Office
    • Rising Stars Network
    • Celebrating 100 Years
    • New England Council Fellows Program
    • Sponsorship Opportunities
  • Contact

News

Aug 18, 2022Blog | Member News, Healthcare, Technology & Innovation

Bristol Myers Squibb teams up with GentiBio to create cell therapies for Crohn’s other conditions

New England Council member, Bristol Myers Squibb has partnered with GentiBio to research new cell therapies for autoimmune and inflammatory conditions. Together these two companies will develop treatments that stop immune responses to aid people with inflammatory bowel disease including Crohn’s and ulcerative colitis. As other biotech firms have focused on cancer, this partnership will be a unique focus on how autoimmune diseases will affect up to 3.5 million people by the year 2030.

The cell therapy put forth by Bristol Myers Squibb and GentiBio will use regulatory T cells which will be aimed at controlling inflammation. Using these specific cells biomedical engineers to target the inflammation in the intestines, stop any out unruly response by the immune system and start the healing process. Along with cell therapy, bioengineers will work on a complimentary pill to work as a kind of ‘remote control’ which can allow doctors to adjust the response of the T-cells depending on the patient.

Cofounder and chief executive of GentiBio said “[w]e’re excited to work with a well-established partner such as BMS, given the size of the indication and given the potential impact.”

The New England Council would like to commend Bristol Myers Squibb and its new partner GentiBio for its dedicated work developing new therapies.

Read more from the Boston Globe.

Council Related News
Read Article Blog | Member News, Healthcare

Point32Health hires new CEO

Read Article Blog | Member News, Healthcare

Dana-Farber plans to hire 700 new nurses

Read Article Blog | Member News, Transportation & Infrastructure

Massachusetts Port Authority is pushing to make MA a hub for sustainable aviation fuels

Read Article Blog | Member News, Higher Education

Stonehill College to build new on-campus sports arena with $15M grant

Read Article Blog | Member News, Transportation & Infrastructure

Free ASL translation app added in Manchester airport

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit